Ameriprise Financial Inc Adaptimmune Therapeutics PLC Transaction History

Ameriprise Financial Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$3.63 - $6.06 $432,986 - $722,836	-119,280 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$3.76 - $14.16 $15,874 - $59,783	-4,222 Reduced 3.42%	119,280 $686,000
Q3 2018 Nov 14, 2018	SELL	$8.27 - $13.56 $1.02 Million - $1.67 Million	-123,146 Reduced 49.93%	123,502 $1.68 Million
Q2 2018 Aug 14, 2018	BUY	$10.42 - $13.74 $256,967 - $338,842	24,661 Added 11.11%	246,648 $2.93 Million
Q1 2018 May 15, 2018	BUY	$7.1 - $11.56 $1.58 Million - $2.57 Million	221,987 New	221,987 $2.49 Million

113M

77.5K

14.2K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $44.1M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.